VolitionRX Q1 2024 GAAP EPS $(0.10) Beats $(0.11) Estimate, Sales $171.535K Miss $389.500K Estimate
Portfolio Pulse from Benzinga Newsdesk
VolitionRX reported Q1 2024 earnings with a GAAP EPS of $(0.10), beating estimates by 9.09% but missed sales estimates by 55.96%, reporting $171.535K against an expected $389.500K.
May 13, 2024 | 8:57 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
VolitionRX's Q1 2024 earnings report showed a better-than-expected EPS but a significant miss in sales forecasts.
While the EPS beat might be seen positively, the significant miss in sales forecasts could raise concerns about revenue growth and market expectations, potentially leading to mixed short-term market reactions.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100